Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/48646
Full metadata record
???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
---|---|---|
dc.contributor.advisor | 陳青周(Ching-Chow Chen) | |
dc.contributor.author | Chia-Wei Chou | en |
dc.contributor.author | 周家瑋 | zh_TW |
dc.date.accessioned | 2021-06-15T07:06:20Z | - |
dc.date.available | 2014-03-03 | |
dc.date.copyright | 2011-03-03 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-11-25 | |
dc.identifier.citation | Amado, R. G., M. Wolf, M. Peeters, E. {Van Cutsem}, S. Siena, D. J. Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky, S. D. Patterson and D. D. Chang (2008). 'Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.' Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26: 1626-1634.
Apte, S. S. (2004). 'A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family.' Int J Biochem Cell Biol 36: 981-985. Arteaga, C. L. (2007). 'HER3 and mutant EGFR meet MET.' Nat Med 13: 675-677. Banck, M. S. and A. Grothey (2009). 'Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.' Clinical cancer research : an official journal of the American Association for Cancer Research 15: 7492-7501. Baselga, J. and S. M. Swain (2009). 'Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.' Nat Rev Cancer 9: 463-475. Bean, J., C. Brennan, J. Y. Shih, G. Riely, A. Viale, L. Wang, D. Chitale, N. Motoi, J. Szoke, S. Broderick, M. Balak, W. C. Chang, C. J. Yu, A. Gazdar, H. Pass, V. Rusch, W. Gerald, S. F. Huang, P. C. Yang, V. Miller, M. Ladanyi, C. H. Yang and W. Pao (2007). 'MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.' Proc Natl Acad Sci U S A 104: 20932-20937. Berger, S. L. (2007). 'The complex language of chromatin regulation during transcription.' Nature 447: 407-412. Bird, A. (2007). 'Perceptions of epigenetics.' Nature 447: 396-398. Blais, A. (1991). 'Expression of Na(+)-coupled sugar transport in HT-29 cells: modulation by glucose.' Am J Physiol 260: C1245-1252. Bolden, J. E., M. J. Peart and R. W. Johnstone (2006). 'Anticancer activities of histone deacetylase inhibitors.' Nat Rev Drug Discov 5: 769-784. Brandt, B., S. Meyer-Staeckling, H. Schmidt, K. Agelopoulos and H. Buerger (2006). 'Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response.' Clinical cancer research : an official journal of the American Association for Cancer Research 12: 7252-7260. Campbell, N. E., L. Kellenberger, J. Greenaway, R. A. Moorehead, N. M. Linnerth-Petrik and J. Petrik (2010). 'Extracellular matrix proteins and tumor angiogenesis.' J Oncol 2010: 586905. Casneuf, V. F., P. Fonteyne, N. {Van Damme}, P. Demetter, P. Pauwels, B. de Hemptinne, M. {De Vos}, C. {Van de Wiele} and M. Peeters (2008). 'Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.' Cancer investigation 26: 852-859. Chen, C.-J., W.-C. Chang and B.-K. Chen (2008). 'Attenuation of c-Jun and Sp1 expression and p300 recruitment to gene promoter confers the trichostatin A-induced inhibition of 12(S)-lipoxygenase expression in EGF-treated A431 cells.' European journal of pharmacology 591: 36-42. Chou, C.-W. and C.-C. Chen (2008). 'HDAC inhibition upregulates the expression of angiostatic ADAMTS1.' FEBS Letters 582: 4059-4065. Choudhary, C., C. Kumar, F. Gnad, M. L. Nielsen, M. Rehman, T. C. Walther, J. V. Olsen and M. Mann (2009). 'Lysine acetylation targets protein complexes and co-regulates major cellular functions.' Science 325: 834-840. Crazzolara, R., K. Johrer, R. W. Johnstone, R. Greil, R. Kofler, B. Meister and D. Bernhard (2002). 'Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia.' Br J Haematol 119: 965-969. Deribe, Y. L., P. Wild, A. Chandrashaker, J. Curak, M. H. Schmidt, Y. Kalaidzidis, N. Milutinovic, I. Kratchmarova, L. Buerkle, M. J. Fetchko, P. Schmidt, S. Kittanakom, K. R. Brown, I. Jurisica, B. Blagoev, M. Zerial, I. Stagljar and I. Dikic (2009). 'Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6.' Sci Signal 2: ra84. Deroanne, C. F., K. Bonjean, S. Servotte, L. Devy, A. Colige, N. Clausse, S. Blacher, E. Verdin, J. M. Foidart, B. V. Nusgens and V. Castronovo (2002). 'Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.' Oncogene 21: 427-436. Desbois-Mouthon, C., A. Baron, M. J. Blivet-Van Eggelpoel, L. Fartoux, C. Venot, F. Bladt, C. Housset and O. Rosmorduc (2009). 'Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.' Clin Cancer Res 15: 5445-5456. Doyle, K. M., D. L. Russell, V. Sriraman and J. S. Richards (2004). 'Coordinate transcription of the ADAMTS-1 gene by luteinizing hormone and progesterone receptor.' Mol Endocrinol 18: 2463-2478. Drummond, D. C., C. O. Noble, D. B. Kirpotin, Z. Guo, G. K. Scott and C. C. Benz (2005). 'Clinical development of histone deacetylase inhibitors as anticancer agents.' Annu Rev Pharmacol Toxicol 45: 495-528. Egger, G., G. Liang, A. Aparicio and P. A. Jones (2004). 'Epigenetics in human disease and prospects for epigenetic therapy.' Nature 429: 457-463. Engelman, J. A. and L. C. Cantley (2008). 'A sweet new role for EGFR in cancer.' Cancer cell 13: 375-376. Engelman, J. A. and P. A. Janne (2008). 'Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.' Clin Cancer Res 14: 2895-2899. Engelman, J. A., K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C. M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley and P. A. Janne (2007). 'MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.' Science 316: 1039-1043. Ewald, J. (2003). 'Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells.' Experimental Cell Research 282: 121-131. Fakih, M. G., L. Pendyala, G. Fetterly, K. Toth, J. A. Zwiebel, I. Espinoza-Delgado, A. Litwin, Y. M. Rustum, M. E. Ross, J. L. Holleran and M. J. Egorin (2009). 'A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.' Clinical cancer research : an official journal of the American Association for Cancer Research 15: 3189-3195. Fazzone, W., P. M. Wilson, M. J. Labonte, H. J. Lenz and R. D. Ladner (2009). 'Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells.' Int J Cancer 125: 463-473. Ferguson, K. M., M. B. Berger, J. M. Mendrola, H. S. Cho, D. J. Leahy and M. A. Lemmon (2003). 'EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.' Mol Cell 11: 507-517. Fidler, I. J., Z. Weihua, R. Tsan, W.-C. Huang, Q. Wu, C.-H. Chiu and M.-C. Hung (2008). 'Survival of cancer cells is maintained by EGFR independent of its kinase activity.' Cancer cell 13: 385-393. Ganapathy, V., M. Thangaraju and P. D. Prasad (2009). 'Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond.' Pharmacology & therapeutics 121: 29-40. Gao, Y. S., C. C. Hubbert and T. P. Yao (2010). 'The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation.' J Biol Chem 285: 11219-11226. Ghoshal, K., J. Datta, S. Majumder, S. Bai, X. Dong, M. Parthun and S. T. Jacob (2002). 'Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure.' Mol Cell Biol 22: 8302-8319. Gui, C. Y., L. Ngo, W. S. Xu, V. M. Richon and P. A. Marks (2004). 'Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.' Proc Natl Acad Sci U S A 101: 1241-1246. Haggarty, S. J., K. M. Koeller, J. C. Wong, C. M. Grozinger and S. L. Schreiber (2003). 'Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.' Proc Natl Acad Sci U S A 100: 4389-4394. Harari, P. M. and S.-M. Huang (2004). 'Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?' International journal of radiation oncology, biology, physics 58: 976-983. Helmke, B. M., C. Reisser, M. Idzko, G. Dyckhoff and C. Herold-Mende (2004). 'Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck.' Oral Oncol 40: 28-35. Iruela-Arispe, M. L., D. Carpizo and A. Luque (2003). 'ADAMTS1: a matrix metalloprotease with angioinhibitory properties.' Ann N Y Acad Sci 995: 183-190. Ishikawa, N., T. Oguri, T. Isobe, K. Fujitaka and N. Kohno (2001). 'SGLT gene expression in primary lung cancers and their metastatic lesions.' Jpn J Cancer Res 92: 874-879. Jenuwein, T. and C. D. Allis (2001). 'Translating the histone code.' Science 293: 1074-1080. Johnson, A. C., B. A. Murphy, C. M. Matelis, Y. Rubinstein, E. C. Piebenga, L. M. Akers, G. Neta, C. Vinson and M. Birrer (2000). 'Activator protein-1 mediates induced but not basal epidermal growth factor receptor gene expression.' Molecular medicine (Cambridge, Mass.) 6: 17-27. Joseph, J., G. Mudduluru, S. Antony, S. Vashistha, P. Ajitkumar and K. Somasundaram (2004). 'Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB.' Oncogene 23: 6304-6315. Kageyama, R., G. T. Merlino and I. Pastan (1988). 'Epidermal growth factor (EGF) receptor gene transcription. Requirement for Sp1 and an EGF receptor-specific factor.' The Journal of biological chemistry 263: 6329-6336. Koshiji, M., K. K. W. To, S. Hammer, K. Kumamoto, A. L. Harris, P. Modrich and L. E. Huang (2005). 'HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression.' Molecular Cell 17: 793-803. Krejsa, C., M. Rogge and W. Sadee (2006). 'Protein therapeutics: new applications for pharmacogenetics.' Nat Rev Drug Discov 5: 507-521. Kuno, K., K. Bannai, M. Hakozaki, K. Matsushima and K. Hirose (2004). 'The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential.' Biochem Biophys Res Commun 319: 1327-1333. Lee, N. V., M. Sato, D. S. Annis, J. A. Loo, L. Wu, D. F. Mosher and M. L. Iruela-Arispe (2006). 'ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2.' Embo J 25: 5270-5283. Levy, E. M., G. Sycz, J. M. Arriaga, M. M. Barrio, E. M. von Euw, S. B. Morales, M. Gonzalez, J. Mordoh and M. Bianchini (2009). 'Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.' Innate Immun 15: 91-100. Lin, Y. C., J. H. Lin, C. W. Chou, Y. F. Chang, S. H. Yeh and C. C. Chen (2008). 'Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.' Cancer Res 68: 2375-2383. Linardou, H., C. A. Papadimitriou, I. J. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos, P. Kosmidis and S. Murray (2008). 'Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.' The Lancet Oncology 9: 962-972. Luetteke, N. C., H. K. Phillips, T. H. Qiu, N. G. Copeland, H. S. Earp, N. A. Jenkins and D. C. Lee (1994). 'The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase.' Genes & Development 8: 399-413. Lund, A. H. and M. van Lohuizen (2004). 'Epigenetics and cancer.' Genes Dev 18: 2315-2335. Luque, A., D. R. Carpizo and M. L. Iruela-Arispe (2003). 'ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165.' J Biol Chem 278: 23656-23665. Mahraoui, L., A. Rodolosse, A. Barbat, E. Dussaulx, A. Zweibaum, M. Rousset and E. Brot-Laroche (1994). 'Presence and differential expression of SGLT1, GLUT1, GLUT2, GLUT3 and GLUT5 hexose-transporter mRNAs in Caco-2 cell clones in relation to cell growth and glucose consumption.' Biochem J 298 Pt 3: 629-633. Marks, P. A. and W. S. Xu (2009). 'Histone deacetylase inhibitors: Potential in cancer therapy.' J Cell Biochem 107: 600-608. Michaelis, M., U. R. Michaelis, I. Fleming, T. Suhan, J. Cinatl, R. A. Blaheta, K. Hoffmann, R. Kotchetkov, R. Busse, H. Nau and J. Cinatl, Jr. (2004). 'Valproic acid inhibits angiogenesis in vitro and in vivo.' Mol Pharmacol 65: 520-527. Miettinen, P. J., J. E. Berger, J. Meneses, Y. Phung, R. A. Pedersen, Z. Werb and R. Derynck (1995). 'Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor.' Nature 376: 337-341. Mikkelsen, T. S., M. Ku, D. B. Jaffe, B. Issac, E. Lieberman, G. Giannoukos, P. Alvarez, W. Brockman, T. K. Kim, R. P. Koche, W. Lee, E. Mendenhall, A. O'Donovan, A. Presser, C. Russ, X. Xie, A. Meissner, M. Wernig, R. Jaenisch, C. Nusbaum, E. S. Lander and B. E. Bernstein (2007). 'Genome-wide maps of chromatin state in pluripotent and lineage-committed cells.' Nature 448: 553-560. Minucci, S. and P. G. Pelicci (2006). 'Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.' Nat Rev Cancer 6: 38-51. Monneret, C. (2007). 'Histone deacetylase inhibitors for epigenetic therapy of cancer.' Anticancer Drugs 18: 363-370. Nagy, P., D. J. Arndt-Jovin and T. M. Jovin (2003). 'Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells.' Experimental cell research 285: 39-49. Nebbioso, A., N. Clarke, E. Voltz, E. Germain, C. Ambrosino, P. Bontempo, R. Alvarez, E. M. Schiavone, F. Ferrara, F. Bresciani, A. Weisz, A. R. de Lera, H. Gronemeyer and L. Altucci (2005). 'Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells.' Nat Med 11: 77-84. Normanno, N., A. {De Luca}, C. Bianco, L. Strizzi, M. Mancino, M. R. Maiello, A. Carotenuto, G. {De Feo}, F. Caponigro and D. S. Salomon (2006). 'Epidermal growth factor receptor (EGFR) signaling in cancer.' Gene 366: 2-16. Olayioye, M. A., R. M. Neve, H. A. Lane and N. E. Hynes (2000). 'The ErbB signaling network: receptor heterodimerization in development and cancer.' EMBO J 19: 3159-3167. Peart, M. J., G. K. Smyth, R. K. van Laar, D. D. Bowtell, V. M. Richon, P. A. Marks, A. J. Holloway and R. W. Johnstone (2005). 'Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.' Proc Natl Acad Sci U S A 102: 3697-3702. Pili, R., M. P. Kruszewski, B. W. Hager, J. Lantz and M. A. Carducci (2001). 'Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.' Cancer Res 61: 1477-1485. Porter, S., I. M. Clark, L. Kevorkian and D. R. Edwards (2005). 'The ADAMTS metalloproteinases.' Biochem J 386: 15-27. Qian, D. Z., Y. Kato, S. Shabbeer, Y. Wei, H. M. Verheul, B. Salumbides, T. Sanni, P. Atadja and R. Pili (2006). 'Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.' Clin Cancer Res 12: 634-642. Rajpal, S. and A. P. Venook (2006). 'Targeted therapy in colorectal cancer.' Clinical advances in hematology & oncology : H&O 4: 124-132. Reik, W. (2007). 'Stability and flexibility of epigenetic gene regulation in mammalian development.' Nature 447: 425-432. Richon, V. M., T. W. Sandhoff, R. A. Rifkind and P. A. Marks (2000). 'Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.' Proc Natl Acad Sci U S A 97: 10014-10019. Rocks, N., G. Paulissen, F. Quesada Calvo, M. Polette, M. Gueders, C. Munaut, J. M. Foidart, A. Noel, P. Birembaut and D. Cataldo (2006). 'Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC).' Br J Cancer 94: 724-730. Rossig, L., H. Li, B. Fisslthaler, C. Urbich, I. Fleming, U. Forstermann, A. M. Zeiher and S. Dimmeler (2002). 'Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis.' Circ Res 91: 837-844. Ruthenburg, A. J., C. D. Allis and J. Wysocka (2007). 'Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark.' Mol Cell 25: 15-30. Saji, S., M. Kawakami, S. Hayashi, N. Yoshida, M. Hirose, S. Horiguchi, A. Itoh, N. Funata, S. L. Schreiber, M. Yoshida and M. Toi (2005). 'Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.' Oncogene 24: 4531-4539. Santos-Rosa, H. and C. Caldas (2005). 'Chromatin modifier enzymes, the histone code and cancer.' Eur J Cancer 41: 2381-2402. Sasakawa, Y., Y. Naoe, T. Noto, T. Inoue, T. Sasakawa, M. Matsuo, T. Manda and S. Mutoh (2003). 'Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.' Biochem Pharmacol 66: 897-906. Schmidt, M. H. and I. Dikic (2005). 'The Cbl interactome and its functions.' Nat Rev Mol Cell Biol 6: 907-918. Schneider, R., A. J. Bannister and T. Kouzarides (2002). 'Unsafe SETs: histone lysine methyltransferases and cancer.' Trends Biochem Sci 27: 396-402. Shi, X., T. Hong, K. L. Walter, M. Ewalt, E. Michishita, T. Hung, D. Carney, P. Pena, F. Lan, M. R. Kaadige, N. Lacoste, C. Cayrou, F. Davrazou, A. Saha, B. R. Cairns, D. E. Ayer, T. G. Kutateladze, Y. Shi, J. Cote, K. F. Chua and O. Gozani (2006). 'ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression.' Nature 442: 96-99. Spano, J. P., C. Lagorce, D. Atlan, G. Milano, J. Domont, R. Benamouzig, A. Attar, J. Benichou, A. Martin, J. F. Morere, M. Raphael, F. Penault-Llorca, J. L. Breau, R. Fagard, D. Khayat and P. Wind (2005). 'Impact of EGFR expression on colorectal cancer patient prognosis and survival.' Ann Oncol 16: 102-108. Strahl, B. D. and C. D. Allis (2000). 'The language of covalent histone modifications.' Nature 403: 41-45. Tang, B. L. (2001). 'ADAMTS: a novel family of extracellular matrix proteases.' Int J Biochem Cell Biol 33: 33-44. Tong, X., L. Yin and C. Giardina (2004). 'Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition.' Biochemical and biophysical research communications 317: 463-471. Tsankova, N., W. Renthal, A. Kumar and E. J. Nestler (2007). 'Epigenetic regulation in psychiatric disorders.' Nat Rev Neurosci 8: 355-367. Van Cutsem, E., C. H. Kohne, E. Hitre, J. Zaluski, C. R. Chang Chien, A. Makhson, G. D'Haens, T. Pinter, R. Lim, G. Bodoky, J. K. Roh, G. Folprecht, P. Ruff, C. Stroh, S. Tejpar, M. Schlichting, J. Nippgen and P. Rougier (2009). 'Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.' N Engl J Med 360: 1408-1417. Vazquez, F., G. Hastings, M. A. Ortega, T. F. Lane, S. Oikemus, M. Lombardo and M. L. Iruela-Arispe (1999). 'METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity.' J Biol Chem 274: 23349-23357. Waby, J. S., C. D. Bingle and B. M. Corfe (2008). 'Post-translational control of sp-family transcription factors.' Current genomics 9: 301-311. Walther, A., E. Johnstone, C. Swanton, R. Midgley, I. Tomlinson and D. Kerr (2009). 'Genetic prognostic and predictive markers in colorectal cancer.' Nat Rev Cancer 9: 489-499. Wang, Z., C. Zang, K. Cui, D. E. Schones, A. Barski, W. Peng and K. Zhao (2009). 'Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes.' Cell 138: 1019-1031. Wight, T. N. (2005). 'The ADAMTS proteases, extracellular matrix, and vascular disease: waking the sleeping giant(s)!' Arterioscler Thromb Vasc Biol 25: 12-14. Wilson, A. J., D.-S. Byun, N. Popova, L. B. Murray, K. L'Italien, Y. Sowa, D. Arango, A. Velcich, L. H. Augenlicht and J. M. Mariadason (2006). 'Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.' The Journal of biological chemistry 281: 13548-13558. Wilson, A. J., D. S. Byun, N. Popova, L. B. Murray, K. L'Italien, Y. Sowa, D. Arango, A. Velcich, L. H. Augenlicht and J. M. Mariadason (2006). 'Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.' J Biol Chem 281: 13548-13558. Wilson, P. M., A. El-Khoueiry, S. Iqbal, W. Fazzone, M. J. Labonte, S. Groshen, D. Yang, K. D. Danenberg, S. Cole, M. Kornacki, R. D. Ladner and H.-J. Lenz (2010). 'A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.' Cancer chemotherapy and pharmacology: 979-988. Wong, J. J., N. J. Hawkins and R. L. Ward (2007). 'Colorectal cancer: a model for epigenetic tumorigenesis.' Gut 56: 140-148. Yarden, Y. and M. X. Sliwkowski (2001). 'Untangling the ErbB signalling network.' Nat Rev Mol Cell Biol 2: 127-137. Zhang, K. and S. Y. Dent (2005). 'Histone modifying enzymes and cancer: going beyond histones.' J Cell Biochem 96: 1137-1148. Zhao, S., K. Venkatasubbarao, S. Li and J. W. Freeman (2003). 'Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.' Cancer Res 63: 2624-2630. Zhu, P., E. Martin, J. Mengwasser, P. Schlag, K. P. Janssen and M. Gottlicher (2004). 'Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.' Cancer Cell 5: 455-463. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/48646 | - |
dc.description.abstract | 本論文探討組織蛋白去乙醯酶抑制劑(HDACi)影響血管新生抑制分子ADAMTS1及表皮生長因子受器(EGFR)表現之機轉。HDAC抑制劑(HDACi)是一種極具潛力的抗癌藥物且已臨床使用於治療皮膚T細胞淋巴瘤。抑制HDAC會使染色質結構呈現較鬆散之狀態,並啟動許多抑癌基因之表現,使細胞週期停滯或細胞凋亡。本論文發現廣效型HDAC抑制劑(TSA與SAHA)能誘發非小細胞肺癌細胞株(A549)表現血管新生抑制分子ADAMTS1。藉由專一性抑制劑及siRNA技術,證實係HDAC6壓制ADAMTS1之表現。更進一步證明,promoter近端之SP1 binding site為HDACi調控ADAMTS1表現之關鍵區域。HDACi能驅離promoter上之SP1及HDAC6,並吸引組織蛋白乙醯酶CBP結合至promoter上,重新促使ADAMTS1表現。
表皮生長因子受器(EGFR)之表現程度與大腸直腸癌是否轉移或復發有高度的關聯性,EGFR單株抗體亦應用於大腸直腸癌的臨床治療。然而EGFR單株抗體之療效,卻大幅受限於KRAS的突變狀態,突變之KRAS可不經EGFR而持續活化,並傳遞訊息促使癌細胞存活與增生。大腸直腸癌亦高度表現HDAC,其表現程度更與癌症之進程及預後有關。本論文發現,無論KRAS是否突變,HDACi皆顯著抑制大腸直腸癌細胞株之EGFR表現,並抑制EGF所活化之AKT及ERK。同時,HDACi亦降低SGLT1表現並減少細胞對葡萄糖之攝取。EGFR之降低亦貢獻於HDACi所造成之cell cycle arrest及apoptosis。利用overexpression與shRNA技術也證實Class I HDAC (HDAC1、2與3)與EGFR mRNA及蛋白質表現有正相關,於大腸直腸癌病人的檢體中,EGFR與HDAC3兩者之表現亦呈現高度相關。EGFR過度表現時,SP1、HDAC3與CBP皆被吸附至promoter,而HDACi會造成SP1、HDAC3及CBP與 promoter分離並降低histone乙醯化,因而減少EGFR表現。 | zh_TW |
dc.description.abstract | The effects of histone deacetylase (HDAC) inhibitor on the expression of ADAMTS1 and EGFR were investigated in this study. In recent years, HDAC inhibitors are emerging as an exciting new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition accumulates acetylated nuclear histones and loosens the compact chromatin structure to reactivate the silenced tumour-suppressor genes. HDAC inhibitors arrest cell cycle and trigger apoptosis by induction of p21 and death-receptor-mediated extrinsic apoptotic pathways. However, their effects on cancer progression, such as angiogenesis and metastasis, are largely unexplored. The first part of this study demonstrates that pan-HDAC inhibitors, TSA and SAHA, were capable to upregulate the angio-inhibitory ADAMTS1 which was originally silenced in non-small-cell lung cancer. We also demonstrated that specific inhibition or knockdown of HDAC6 led to higher expression of ADAMTS1. We further identify the proximal SP1 binding sites were essential for the TSA-induced ADAMTS1 expression and showed that TSA dispersed the HDAC6 and SP1 and recruited the CBP to the ADAMTS1 promoter.
Expression of the epidermal growth factor receptor (EGFR) is highly correlated with metastasis and recurrence of colorectal cancer (CRC). The clinical strategy is suppressing EGF signaling by EGFR monoclonal antibodies. However, most patients are irresponsive to these antibodies due to the KRAS mutation, which constitutively activates the downstream survival signals bypassing EGFR. Histone deacetylase has also been reported to be overexpressed in colorectal cancer and correlates with poor prognosis. This study demonstrates that HDACi effectively reduced the viability of KRAS wild type and mutant cells in comparison with EGFR antibody, indicating their broad and effective antitumor effect. HDACi were capable to block the EGF signaling via silencing the EGFR expression and concurrent destabilized an active glucose transporter, SGLT1. Furthermore, we demonstrated that the class I HDACs was essential for EGFR gene transcription and a positive correlation between the expression of EGFR and HDAC3 in the specimens of colon cancer patients was also observed. More in-depth, we showed that the binding of SP1 to EGFR promoter and the accompanied recruitment of HDAC3 and CBP are essential for EGFR expression. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T07:06:20Z (GMT). No. of bitstreams: 1 ntu-99-D94443005-1.pdf: 4786993 bytes, checksum: 9d07c17a95eb1b67be84b4f62ef6aed0 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | Abbreviation 2
中文摘要 4 Abstract in English 5 Chapter I. Introduction: 6 1. Epigenetics 6 2. Histone modifications and Histone code hypothesis 10 3. Histone deacetylase 14 4. Histone deacetylase (HDAC) inhibitors 17 5. ADAMTS1 21 6. EGFR and Target Therapy of Colorectal Cancer 25 7. Experimental rationale 31 Chapter II. Materials and Methods 32 Chapter III. HDAC inhibition upregulates the expression of angiostatic ADAMTS1 37 Chapter IV. HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells 50 Chapter V. Conclusion and Perspective 68 Reference 71 Publications and Honors 80 | |
dc.language.iso | en | |
dc.title | HDAC inhibitors調控ADAMTS1及EGFR表現之研究 | zh_TW |
dc.title | Regulation of the expression of ADAMTS1 and EGFR by HDAC inhibitors | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 楊春茂(Chuen-Mao Yang),吳明賢(Ming-Shiang Wu),黃偉謙(Wei-Chien Huang),顏茂雄(Mao-Hsiung Yen) | |
dc.subject.keyword | 組織蛋白去乙醯酶,表皮生長因子受器,ADAMTS!, | zh_TW |
dc.subject.keyword | HDAC,EGFR,ADAMTS1, | en |
dc.relation.page | 80 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-11-26 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
Appears in Collections: | 藥理學科所 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
ntu-99-1.pdf Restricted Access | 4.67 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.